Back to discover
Drug

Osilodrostat phosphate

Approved · EMA

Also known as Isturisa, osilodrostat (as phosphate).

RxNorm2286253
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Isturisa (EMA)

Regulatory2020-01-09EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Osilodrostat phosphate
Aliases & brands
Isturisaosilodrostat (as phosphate)
RxNorm CUI
2286253
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2020-01-09
Latest approval
2020-01-09
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2020-01-09Approval
Approval: Isturisa (EMA)

Indication: Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.